Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19

NCT04751682 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV Infection

Interventions

BIOLOGICAL: BBV154 Vaccine
BIOLOGICAL: Placebo

Sponsor

Bharat Biotech International Limited